Project Grant HT94252310959
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$16M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98103, USA
Similar Awards
The Department of Defense's Defense Health Agency has awarded a $4,876,076 Project Grant to Washington University to develop a novel point-of-care multiplex device for classifying molecular phenotypes of acute respiratory distress syndrome and sepsis. This research falls under the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The grant has a performance...
The Defense Health Agency awarded a $1,523,243 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Medstar Health Research Institute Inc. to evaluate the use of intravesical gentamicin coupled with the probiotic Lactobacillus rhamnosus for improving urinary health. The project will involve pre-clinical studies at Loyola University of Chicago and the University of Pittsburgh to determine the optimal administration protocols, as well as a pilot clinical...
This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a study on the use of intravesical gentamicin coupled with Lactobacillus rhamnosus for urinary health. The total funding amount is $126,166.00, with the award date of September 1, 2024 and an ultimate completion date of August 31, 2027. The prime awardee is Medstar Health Research Institute Inc., a non-profit organization that has extensive...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $759,974 to Washington State University to develop a novel technique for introducing mutations in the native VlsE gene of Borrelia burgdorferi. The objective is to test several mechanistic concepts of VlsE-mediated immune evasion. This 3-year research project, starting on May 1, 2024 and ending on April 30, 2027, aims to advance the...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
This Federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $504,678 in funding to the Mountain Home Research & Education Corporation for a research project titled "LONG NONCODING RNAS IN VIRAL LYMPHOMAS". The award period runs from September 30, 2023 to September 29, 2025. The project aims to conduct basic, translational, and clinical research related to military medicine, with a focus on...
The Department of Defense's Military Medical Research and Development (CFDA 12.420) program awarded a $300,000 Project Grant to Duke University to investigate the "Complement-Activating Properties of Anti-Sm/RNP Antibodies in SLE". This 2-year research effort, starting on September 1, 2024 and ending on August 31, 2026, aims to advance biomedical research that can transform healthcare for military service members, veterans, and the broader public. The Military Medical Research and...
The federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), part of the 93.350 CFDA program, will support the development of a novel biosensor for the detection of bacterial endotoxins. Through this $290,066 award, the awardee Monod Bio, Inc. will focus on (I) computational design and experimental selection of functional lipopolysaccharide (LPS) bioluminescent biosensors, (II) in vitro evolution of these biosensors to optimize sensitivity and stability,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,875 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona to advance a platform technology for Clostridioides difficile infection (CDI) treatment using antisense oligonucleotides (ASOs). The key products and services to be delivered under this 2-year grant include: In vitro studies to evaluate the minimum inhibitory concentration (MIC) and resistance...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $300,001 to Fimbrion Therapeutics Inc. to develop novel heterocyclic inhibitors of the QcrB respiratory protein as potential treatments for infections caused by nontuberculous mycobacteria (NTM). The key objectives of this R&D project are to optimize the drug-like properties of the QcrB inhibitor compounds, demonstrate their potency...